Dr. Roger McIntyre

Braxia Scientific Corp., (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announced the filing of its financial statements and management discussion and...

Field Trip (NASDAQ: FTRP), Wesana (OTCQB: WSNAF), Braxia (OTC: BRAXF) and Irwin Naturals (OTC: IWINF) released their quarterly results. Field Trip Health & Wellness Ltd.  Psychedelic-assisted therapy provider Field Trip (TSXV: FTHW) reported its fiscal and business results...

A researcher and provider of ketamine-assisted treatments for mental health conditions, Braxia Scientific Corp. (OTC: BRAXF) has completed the acquisition of the issued and outstanding stock of U.S.-based, private telemedicine company KetaMD Inc., with the goal of addressing mental health issues by...

Braxia Scientific Corp. (OTCPK:BRAXF) (CSE:RAX) (FWB:4960) recorded revenue of $1.49 million for the fiscal 2022 year ended March 31, 2022 compared with revenue of $1.008 million for the year ended March 31, 2021. On a year-over-year basis, revenue increased 47.5%. Fiscal 2022 Financial Highlights...

Psychedelic-focused health company Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) recently made a string of announcements. The company confirmed Dr. Roger McIntyre as its new CEO, a private placement raise of $10 million and the acquisition of a California-based ketamine treatment centre which marks...